Telecanthus | Jotup

Bausch + Lomb Launches Blink™ NutriTears® Clinically Proven Nutritional Supplement for Dry Eyes in the United States

Retrieved on:

понедельник, июня 3, 2024

“With Blink NutriTears, consumers now have a first-of-its-kind clinically proven nutritional supplement that helps hydrate their eyes from within and provides long-lasting relief.

Key Points:

“With Blink NutriTears, consumers now have a first-of-its-kind clinically proven nutritional supplement that helps hydrate their eyes from within and provides long-lasting relief.
It will be an outstanding complement to our growing dry eye portfolio.”*
Approximately 150 million adults experience symptoms of dry eyes in the United States.
It was also shown to clinically help tears stay on the eyes for 33% longer.1*
"Blink NutriTears demonstrated consistent positive results across two distinct studies.
"With its unique formulation, I anticipate Blink NutriTears will become an important addition to dry eye management strategies."

Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis

Retrieved on:

вторник, мая 28, 2024

RCT, Patient, Telecanthus, DED, MD, Principal, Entrepreneurship, Pharmaceutical industry

Patients previously treated with Restasis® (cyclosporine ophthalmic emulsion 0.05%) prescription eyedrops (“Restasis”) had additional clinically meaningful improvements in the signs and symptoms of dry eye disease (“DED”) when crossed over to TearCare .

Key Points:

Patients previously treated with Restasis® (cyclosporine ophthalmic emulsion 0.05%) prescription eyedrops (“Restasis”) had additional clinically meaningful improvements in the signs and symptoms of dry eye disease (“DED”) when crossed over to TearCare .
“Phase 2 of the RCT again demonstrates the clinical effectiveness of TearCare.
Phase 1 of the SAHARA RCT included 345 subjects at 19 sites in 11 states randomized 1:1 to either TearCare or Restasis1.
In contrast, Symptoms Assessment in Dry Eye (“SANDE”) scores showed statistically significant improvement after the cross over to TearCare.

Bausch + Lomb Announces Presentation of New Scientific Data and Evaluations Featuring Consumer, Vision Care and Pharmaceutical Products at Optometry’s Meeting®

Retrieved on:

вторник, мая 28, 2024

The OnDemand ePosters will feature new data on the early adoption of MIEBO and real-world patient experiences with Bausch + Lomb INFUSE® Multifocal silicone hydrogel daily disposable contact lenses.

Key Points:

The OnDemand ePosters will feature new data on the early adoption of MIEBO and real-world patient experiences with Bausch + Lomb INFUSE® Multifocal silicone hydrogel daily disposable contact lenses.
“Evaluation of the Efficacy of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution.” Evans et al.
“Improvement in Non-Invasive Tear Break-Up Time after Instillation of One Drop of Brimonidine Tartrate 0.025%.” Moore et al.
During the event, attendees will have the opportunity to learn about Bausch + Lomb’s latest innovations, including Bausch + Lomb INFUSE® for Astigmatism and Blink NutriTears.

Upneeq® Wins 2024 Shape Skin Award, “Best for Lift”, in the Professional Treatment Category

Retrieved on:

пятница, мая 17, 2024

RVL Pharmaceuticals announced today that its prescription eye drop, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as a 2024 Shape Skin Award winner by Shape Magazine, named “Best for Lift” in the professional category.

Key Points:

RVL Pharmaceuticals announced today that its prescription eye drop, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as a 2024 Shape Skin Award winner by Shape Magazine, named “Best for Lift” in the professional category.
The product was also named as a "Best Professional Grade'' treatment by editors in 2022 and received a 2023 Shape Beauty Award for “Best In-Office" treatments.
37 winners were ultimately chosen, and judges awarded Upneeq for its subtle but noticeable lift for droopy eyelids.
“Shape is an empowering and trusted voice in health and beauty with a committed community to quality self-care.

Harrow Announces First Quarter 2024 Financial Results

Retrieved on:

понедельник, мая 13, 2024

Biotechnology, Pharmaceutical, Optical, Medical Supplies, Surgery, Health, FDA, Clinical Trials, Retina, Letter, Telecanthus, Multimedia

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2024.

Key Points:

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2024.
The Company also posted its first quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com .
The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and future expectations for the business.
“I am very pleased with the success we had in all three of these areas during the first quarter, and I remain optimistic for 2024 based on what we are seeing in the second quarter.

NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms

Retrieved on:

понедельник, мая 13, 2024

Biotechnology, Health, Pharmaceutical, Optical, Medical Supplies, Chek, Patient, Telecanthus, Eye, Hygiene, Prevalence, Specialization, NBY, Hypochlorous acid, Demodex, Cosmetics

The new Avenova product bundles align with findings among optometrists surveyed in the Eyes on Eyecare 2024 Dry Eye Report of the multifactorial nature of dry eye disease and the recommendation that personalized treatment beyond artificial tears may be important for successful management.

Key Points:

The new Avenova product bundles align with findings among optometrists surveyed in the Eyes on Eyecare 2024 Dry Eye Report of the multifactorial nature of dry eye disease and the recommendation that personalized treatment beyond artificial tears may be important for successful management.
“Our new Avenova product bundles align with where we see the market going, as confirmed by the 2024 Dry Eye Report.
In addition to Avenova spray, the Avenova over-the-counter product line includes the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, Avenova Warm Eye Compress to soothe the eyes and the i-Chek by Avenova to monitor physical eyelid health.
The 2024 Dry Eye Report surveyed 337 optometrists across the U.S., with the majority as primary eye care and dry eye specialists.

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Retrieved on:

четверг, мая 9, 2024

Pain, Cell, Telecanthus, Endothelium, Tissue, Paratriathlon, DED, Eye, ARVO, Disease, Therapy, Patient, SWAP, Irritation, Regeneration, Annual general meeting, Vaccine

“These early results are important as Fuchs’ Endothelial Cell Dystrophy and Dry Eye Disease are severe diseases with few effective treatments available.

Key Points:

“These early results are important as Fuchs’ Endothelial Cell Dystrophy and Dry Eye Disease are severe diseases with few effective treatments available.
The company evaluated a therapeutic approach to stimulate endothelial cell proliferation as human corneal endothelial cells have a limited capacity to regenerate.
The lead molecule, a Surrozen Fzd 1/2/7 SWAP antibody, increased proliferation of endothelial cells in vitro in human cells.
Currently, there is no epithelial regeneration strategy available as treatment usually consists of anti-inflammatory topical eye drops and tear replacements.

Surrozen Provides First Quarter 2024 Financial Results and Business Update

Retrieved on:

среда, мая 8, 2024

Respiratory Research, Telecanthus, Liver disease, Boehringer Ingelheim, Publication, Research, Partnership, Development, Administration, ARVO, Therapy, Pulmonary fibrosis, Retina, Patient, Liver, Eye, Fibrosis, Regeneration, SWAP

SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided first quarter 2024 financial results and business updates.

Key Points:

Financial Results for the First Quarter Ended March 31, 2024
Cash Position: Cash and cash equivalents were $27.3 million as of March 31, 2024, compared to $36.0 million as of December 31, 2023.
However, inclusive of proceeds from a financing completed in April 2024, the proforma cash for March 31, 2024 would be $43.2M.
Restructuring: Restructuring charges for the first quarter ended March 31, 2024 were zero, as compared to $1.2 million for the same period in 2023.
Net Loss: Net loss for the first quarter ended March 31, 2024 was $8.8 million, as compared to $14.3 million for the same period in 2023.

Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

Retrieved on:

среда, мая 8, 2024

FDA, Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Telecanthus, NDA, Food, New Drug Application, RASP, Environment, Patient, DSM-IV codes, Clinical trial, Therapy, Pharmaceutical industry

Contingent on positive results from the clinical trial, Aldeyra expects to resubmit the NDA of reproxalap for the treatment of dry eye disease to the U.S. Food and Drug Administration (FDA) in the second half of 2024.

Key Points:

Contingent on positive results from the clinical trial, Aldeyra expects to resubmit the NDA of reproxalap for the treatment of dry eye disease to the U.S. Food and Drug Administration (FDA) in the second half of 2024.
Aldeyra intends to include in the potential NDA resubmission a draft label describing chronic and acute improvement in symptoms and ocular redness.
To Aldeyra’s knowledge, the draft label could represent the first dry eye disease label that incorporates clinical data assessed acutely in a dry eye chamber, and potentially the first dry eye disease label that includes reduction in ocular redness for a chronically administered drug.
In the clinical trial, patients are administered vehicle (the drug product without the active ingredient) before and during exposure to a dry eye chamber.

NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon

Retrieved on:

вторник, мая 7, 2024

Biotechnology, Online Retail, Health, Cosmetics, Retail, Chek, Amazon (company), Marketing, Telecanthus, Growth, NBY

(NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces record ordered product sales during the month of April for its Avenova-branded eyecare products on Amazon.com, the Company’s largest sales channel.

Key Points:

(NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces record ordered product sales during the month of April for its Avenova-branded eyecare products on Amazon.com, the Company’s largest sales channel.
“We are very excited about our progress with ordered product sales for Avenova on Amazon, including setting a record for ordered product sales in March and then immediately beating that record in April.
Ordered product sales in the previous two months have even eclipsed prior months that included record sales days during Prime Day events,” said Justin Hall, CEO of NovaBay.
We attribute these unparalleled sales months to the high quality of our Avenova products and the effectiveness of those cost-efficient marketing programs.